Our mission is to improve human health and well-being through innovative diagnostic products and global partnerships.
We are focused on selling a wide range of specialist products, primarily in the immunoassay, in-vitro diagnostics (IVD) market within three segments: Allergy, Health & Wellbeing and Global Health.
Originally founded in Scotland in 1987, Omega Diagnostics Ltd's global reputation stems from beginnings as a manufacturer of tests for a range of infectious diseases such as syphilis, dengue fever and malaria. Our export success was officially recognised with the Queen’s Award for Export Achievement in 1993, providing a solid foundation for future success.
In 2006, Omega Diagnostics Group PLC was formed with a strategy to acquire additional products through acquisitions and now focuses on selling a wide range of specialist products, primarily in the immunoassay, in vitro diagnostics (IVD) market within three segments: Allergy, Health & Wellbeing and Global Health.
With our global headquarters based in Scotland, we have subsidiaries in Littleport (UK), Devon (UK) and Mumbai (India), with each site possessing ISO 13485 and ISO 9001, and compliant with directive 98/79/EC, on In Vitro Diagnostic (IVD) Medical Devices.
Our diagnostic kits and systems are found in hospitals, blood banks, clinics and laboratories around the world and produce information used by physicians and practitioners to diagnose disease, make treatment decisions and monitor patients.
Our product range was extended following the acquisition of Genesis Diagnostics Ltd and Cambridge Nutritional Sciences Ltd in September 2007, giving our customers access to tests for the fast-growing area of food intolerance testing.
In 2010, Omega Diagnostics Group acquired the IVD division of allergy and specific immunotherapy specialist Allergopharma Joachim Ganzer KG, giving further access to a range of allergy tests for over 600 allergens.
In 2018, a restructure of our operations was carried out whereby our four UK companies were amalgamated into one entity, Omega Diagnostics Ltd. Further to this, in 2018 we disposed of our infectious disease business, with the exception of VISITECT CD4, to Novacyt SA, an international specialist in clinical diagnostics.
Today, we are one of the UK's leading companies in the fast growing area of immunoassay and we have a global presence in over 75 countries worldwide.